• Age-adjusted D-dimer cut-offs decrease the false positives in the elderly.
• Age-adjusted D-dimer cut-offs decrease the false positives in the elderly.
• Four D-dimer assays were compared in venous thromboembolism outpatients in an emergency ward.
• Age-adjusted cut-off resulted in improved specificity with maintained sensitivity for all assays.
• There was a substantial decrease in false positive results, especially in the older population.
Summary. Background:
The study compares different Ddimer assays and age-adjusted cut-offs in outpatients with suspected venous thromboembolism (VTE). The plasma concentration of this sensitive biomarker is increased by activated coagulation, but also by several conditions that are linked to an increased risk of VTE. One such condition is old age, which poses a common clinical problem where many prefer not to analyze D-dimer in elderly patients. Age-adjusted cut-offs have been validated for both deep venous thrombosis (DVT) and pulmonary embolism, aiming to increase specificity without notably decreasing sensitivity. Objectives: We evaluated four common D-dimer assays in parallel, with and without applying age-adjusted cut offs for VTE. Patients/methods: The prospective single-center study was conducted in 940 outpatients attending the emergency department with clinically suspected pulmonary embolism or DVT. Four automated D-dimer assays were compared (Siemens INNOVANCE
Introduction
Venous thromboembolism (VTE) is a globally widespread disease, primarily comprising deep venous thrombosis (DVT, 60%) and pulmonary embolism (PE, 40%) [1] . In Europe about 12% of all deaths are reported to be caused by PE [1] and half of all PEs identified at autopsy are previously undiagnosed [2] . VTE also causes considerable acute and long-term morbidity [3, 4] and accounts for great costs for society [4, 5] . Diagnosis of VTE is based on the biomarker D-dimer for excluding low probability VTE, and imaging techniques to verify mid/high probability VTE. There is a distinct risk of delayed diagnosis or misdiagnosis because symptoms are often diffuse and the imaging techniques are both time consuming and expensive. Computer tomography pulmonary angiography (CTPA), which is the preferred technique for verifying PE, is also associated with exposure to radiation and intravenous contrast, both of which can have iatrogenic adverse effects [6, 7] .
D-dimer assays generally have a high diagnostic sensitivity, but specificity is low as a result of the pathophysiology of this biomarker. The plasma concentration of D-dimer increases in thrombosis and coagulation activation, but also in several other conditions [8] , such as pregnancy, cancer, trauma, inflammation and infection, and with age [9] . Many of these conditions are associated with an increased risk of venous thrombosis and are frequently encountered in VTE patients. For example, the incidence of VTE, as well as the plasma concentration of D-dimer, increases with age. Even in a healthy population aged ≥ 70 years, 50% have a Ddimer concentration above the cut-off (0.5 mg L À1 fibrin equivalent units [FEU] ) [10] . Some advocate that Ddimer testing should be entirely avoided in the elderly [10, 11] , but the effect of this approach would be that patients had to undergo imaging techniques instead, even if the probability of VTE were low. Age-adjusted cut-offs have been previously validated and recommended in DVT and PE [12] [13] [14] [15] [16] [17] [18] to increase specificity in older patients while preserving sensitivity. However, this has been questioned [19] [20] [21] , and a recent Cochrane review of D-dimer to rule out pulmonary embolism did not find enough evidence to recommend age-adjusted cut-offs [22] . The present study evaluates age-adjusted D-dimer cutoffs in a single-center study in Swedish outpatients with suspected DVT or pulmonary embolism. The evaluation was conducted as a comparison of different D-dimer assays because D-dimer results cannot easily be compared between assays. The poor analytical comparability is a result of size heterogeneity of the D-dimer fragments, and because assays have different reactivity for the various fragment lengths [23] . There is presently no international reference calibrator for D-dimer because the balance of different fragment sizes varies inter-individually as well as with clinical conditions [24] . Conditions with an interrupted blood flow, such as thromboembolism, tend to produce shorter fragments, whereas conditions with a maintained flow such as disseminated intravascular coagulation (DIC) generally produce longer fragments [23] . To improve the comparability of D-dimer, results are preferably reported in mg L À1 fibrin equivalent units (FEU) or mg L À1 D-dimer equivalent units (D-DU) [25] .
The aim of the present study was to evaluate four different D-dimer assays in fresh plasma and to verify previous evidence that age-adjusted D-dimer cut-offs may increase the specificity and reduce the rate of false positive D-dimer results for older patients, without compromising the sensitivity.
Materials and methods

Patients
In this study, 954 outpatients with clinically suspected PE or DVT in a lower limb were prospectively recruited between April 2014 and May 2015 from the emergency department of Karolinska University Hospital in Huddinge, Stockholm. The study protocol was approved by the regional ethics review board in Stockholm (DNR 2013-2143-31-2), and all participants provided an informed written (consent) at enrolment. Patients were included regardless of clinical probability, in order to evaluate the full spectrum of samples that are sent to the laboratory, with regard to the certainty of excluding VTE. The study design is summarized in Fig. 1 . Table 1 ). The assays were calibrated with the calibrators of the respective manufacturers. Roche Tina-quant D-dimer was the assay in clinical use, but all four assays were performed in the routine laboratory system, and hence the other three assays were performed only as far as practically possible for the laboratory personnel. cases were because of a problem with reagent delivery). Diagnostic characteristics for the assays were based on the cut-off values recommended by the manufacturer and age-adjusted cut-offs were calculated as age 9 0.01, according to Douma et al. [26] . Age adjusted cut-off values were thus only implemented in patients aged ≥ 50 years (see Table 1 ). For MRX D-dimer the age-adjusted cut-off values were calculated as age 9 0.004, which maintained the ratio between the MRX cut-off and the FEU cut-offs (9 0.4).
Reference methods
Diagnostic imaging was performed in 516 patients with high clinical probability of VTE and/or positive Tinaquant D-dimer. CTPA or ventilation/perfusion lung scintigraphy was performed for suspected PE and Doppler ultrasonography for suspected DVT (alternatively lower-limb vein compression ultrasonography, CUS, n = 10). Verified VTEs were classified into segmental or subsegmental PE and proximal or distal DVT. Non-VTE was verified by absence of VTE in a 3-month follow-up of medical records; additionally, in n = 391, imaging techniques had also been performed ( Fig. 1 ).
Clinical data
Clinical data were collected from medical records by MF and any ambiguous cases were confirmed by two Table 1 Evaluated assays, samples in evaluation, manufacturers' recommended cut-off, applied age-adjusted cut-off and instrument used for evaluation.
D-dimer assay
Samples (n) Cut-off Age-adjusted cut-off (for patients ≥ 50 years) Instrument
hematologists specialized in coagulation disease (MH and ML). Fourteen patients were excluded from the study because after revision of patient records the diagnosis could not be confirmed. In only one patient did a thrombosis occur within the 3-month follow-up period. This was a 47-year-old man who was included because of a 12-h history of increasing pain and redness in his right calf. The symptoms were clinically interpreted as very low probability of DVT despite positive D-dimer, and the patient was dismissed from the emergency department without imaging. Sixteen days later the man had a new episode of pain and swelling, at which time a Doppler ultrasonography showed a thrombosis in the right popliteal and femoral veins. The case was classified as negative in this study, and D-dimer classified as false positive for all applied assays.
Statistical methods
The diagnostic performance of the four D-dimer assays was compared before and after implementation of ageadjusted cut-offs by the following statistical methods: sensitivity, specificity, pre-test probability, negative predictive value (NPV), positive predictive value (PPV), efficiency (true results/total results), negativity rate (% Neg), false positive rate (% FP) and number needed to test (NNT) to rule out the diagnosis in one patient (the inverse proportion of patients with a negative D-dimer) [27] . We calculated receiver operator curves (ROCs), the area under the ROC curves (AUC) [28] and the cumulative data analysis curves (CDA) [29] .The AUC is used to summarize the overall diagnostic value by a test and describes the ability of a test to correctly classify those with disease and those without [30] , and the CDA illustrates the relation between the sensitivity and specificity depending on the quantity value/cut-off. Concordance of the different assays was illustrated in scatter plots, limited to < 2 mg L À1 . The statistical analysis was performed using SPSS 23 and MS Excel.
Results
VTE was found in 125 of the 940 included patients (13.3%, of which 3.7% were PE and 9.6% DVT) (see Table 2 ). In 379 patients with suspected PE, 9% had PE (80% segmental, 20% subsegmental), and in 561 with suspected DVT, 16% had DVT (64% proximal, 36% distal). Because of differences in cohort sizes, the pretest probabilities varied from 0.13 for Tina-quant, INNOVANCE (Table S1 ).
The diagnostic performances of the assays are displayed in Table 3 , with a comparison of the two different cut-off strategies. The sensitivity of all assays was high, with only six cases falsely classified as negative by any assay. All false negative cases are summarized in Table 4 . The specificity was lower among patients ≥ 50 years of age, and decreased with increasing age (Table S2) .
The concordance between the assay results is visualized as scatter plots with cut-off lines, focusing on results close to the cut-off values (< 2 mg L À1 ), which is considered the clinically relevant interval (Fig. 4) . In the comparison of Tina-quant and MRX, an outlier was identified. This patient with a distal DVT was identified as suffering from a serious autoimmune disease, which may interfere with immunological assays. When age-adjusted cut-offs were applied, all assays maintained their sensitivities and the specificities increased by 6-7% (Table 3 ). The decrease in number needed to test was also modest: 0.15-0.28 for the respective assays ( Table 3 ). The false positive results decreased by 5-6 percent units (Table 3) , with a corresponding increase in negative results for all assays (Table 3) as those false positives became true negatives. The decrease in % FP increased by age (Fig. 3) . In patients ≥ 80 years, the % FP decreased by 20% for Tina-quant D-dimer, 13% for INNOVANCE Ò D-dimer, 16% for MRX D-dimer and (Fig. 3) .
Discussion D-dimer is still the only biomarker used for diagnosis of VTE, although a low specificity (i.e. false positive results) presents a significant problem, particularly in the elderly-patient population burdened with comorbidity.
The examined age-adjusted cut-offs increased specificity for VTE while retaining the high sensitivity; this indicates that the sensitivity of the D-dimer assays is rather resistant to changes in the cut-off (below 1 mg L À1 FEU) (Fig. 2) . Age-adjusted cut-offs will improve the diagnostic ability to rule out VTE; however, the specificity has not improved enough to alter any clinical algorithms (i.e. not confirm VTE). An important aspect is that in the older patients age-adjusted cut-offs markedly decreased the rate of false positive results, and hence markedly increased specificity. This reintroduces D-dimer as a viable option for ruling out VTE in that expanding population, where the natural increase in D-dimer concentration by age has been a considerable confounding factor in its rational use.
The diagnostic performance was equally good in all assays evaluated in this study, judged by the sensitivities and the AUCs of the ROC analyses. All assays had sensitivity ≥ 96% at the cut-off recommended by the manufacturer even in this mixed clinical probability cohort (except MRX D-dimer at 94%). Roche Tinaquant could even fulfill the recommendations for D-dimer assays used in patients with low or intermediate pretest probability of VTE by the Clinical and Laboratory Standards Institute (CLSI) [31] ; that is, sensitivity ≥ 97% (95% lower limit confidence interval [CI] of ≥ 90%) and NPV ≥98% (95% lower limit CI of ≥ 95%).
Because the clinical pre-test probabilities of VTE were not defined, the NPVs/PPVs and efficiencies calculated in this study can only be applied to a VTE population with both high and low clinical suspicions. This does not accord with the recommended diagnostic algorithm, but nevertheless is not uncommon in clinical practice [32] . It was recently suggested that D-dimer (< 0.75 mg L À1 FEU) could be used without previous assessment of clinical pre-test possibility to exclude PE [33] ; however, this could not be verified in a meta-analysis [34] . It is noteworthy, with respect to the high sensitivities observed in the present cohort of mixed clinical probability, that the false negative results observed in the study were minor thromboses (i.e. subsegmental PEs and distal DVTs, with only one exception) ( Table 4) . Many D-dimer evaluations do in fact classify these minor VTEs as VTE negative. There is currently no international consensus as to whether or not minor VTEs should generally receive anticoagulant treatment [35] . The most recent guidelines propose active clinical surveillance [36] , although many clinicians treat all detected minor PEs and DVTs. The evaluated assays' performances raise another question: is the general cut-off set somewhat too high for patients younger than 50 years? In the population < 50 years (n = 346), the sensitivities of the assays were far below the CLSI requirements for sensitivity. A study validating the manufacturers' recommended cut-off values in populations < 50 years old would be of interest, and this has recently been addressed by Proschaska et al. [37] .
A limitation of the present study was that the cohort included both PE and DVT. However, it has previously been shown that D-dimer can be used in both populations with unchanged sensitivity and specificity if the same cut-off is used in both groups [14] . Had the study population been larger, results could have been sub-stratified to investigate assay performances in the PE and DVT groups separately and for patients < 50 years of age. The limitation of study size was most pronounced in the relatively few patients tested by Stagos STA Ò -Liatest Ò D-Dimer, resulting in wider confidence intervals for this assay. However, our study is, to the best of our knowledge, one of the largest single-center studies investigating age-adjusted cut-offs and the only large study comparing four different D-dimer assays in fresh plasma. We chose to include some results from Stago in spite of the few samples, because it was at least possible to discern that the assay seemed comparable to the other three assays.
It has previously been debated whether differences in assay performance between studies depend on differences in assay or patient characteristics [38] . However, determining the reasons for differences between studies clearly necessitates simultaneous comparisons of D-dimer assays in parallel with new clinical trials. Patient characteristics play an important part, but it is also well established that comparability between D-dimer assays is poor, because of the fact that the fibrin degradation products are of heterogeneous size and the automated immunochemical assays of D-dimer have different affinity for the various fragment sizes [23, 24] . This is illustrated by the dispersion of assay results in our scatter plots (Fig. 4) . The comparison of four different assays is a key strength of this study. The scatter plots also show that there are cases around the cut-off that were negative with Tina-quant D-dimer, but positive with the other assays. These patients would ideally have been radiologically examined but have instead been actively followed in medical records as well as instructed to return to the emergency department if symptoms remain. Tina-quant D-dimer was the assay clinically used in our laboratory at the time of the study, and therefore the one that decided all clinical work-ups.
The advantages of age-adjusted D-dimer cut-offs are not uncontroversial [39] and the concept has also been challenged in a few recent studies [19] [20] [21] . These studies have shown an equal improvement of specificity and % Neg between age-adjusted cut-offs and general increase of cut-offs in a low-risk population with a corresponding low incidence of VTE at 6.6% [19] and 7.8% [20, 21] for the two studies, respectively. The reduction in % FP was not specified in any of those studies.
Conclusion
The present prospective single-center study adds to the significant efforts of recent years that support ageadjusted cut-offs for D-dimer in DVT and PE. We have shown that in more than 5% of all patients with suspected disease, the extra time and cost of imaging techniques to rule out VTE could be avoided (Table 3) . In elderly patients this elimination of unnecessary imaging could even affect as many as 20% of patients with suspected VTE (Fig. 3) .
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